TY - JOUR
T1 - Methodologies and strategies for the bioengineering of lantibiotics
AU - Nagao, Jun ichi
AU - Nishie, Mami
AU - Sonomoto, Kenji
PY - 2011/8
Y1 - 2011/8
N2 - Lantibiotics are ribosomally synthesized, post-translationally modified, peptide antibiotics containing unusual amino acids such as dehydrated amino acids and lanthionine. These unusual amino acids impose conformational constraints on the peptide and contribute to the biological activity and high physicochemical stability of lantibiotics. Recent researches on the modification enzymes responsible for dehydration and cyclization have considerably increased our understanding of their molecular characteristics and relaxed specificity. These insights enabled us to exploit these modification enzymes for developing new lantibiotic variants with improved therapeutic potential. Several methodologies have been explored to engineer novel lantibiotics. Here, we outline the current knowledge of modification enzymes. We also describe the methodologies and strategies used to engineer lantibiotics and provide some examples of successful generation of lantibiotics with enhanced activity.
AB - Lantibiotics are ribosomally synthesized, post-translationally modified, peptide antibiotics containing unusual amino acids such as dehydrated amino acids and lanthionine. These unusual amino acids impose conformational constraints on the peptide and contribute to the biological activity and high physicochemical stability of lantibiotics. Recent researches on the modification enzymes responsible for dehydration and cyclization have considerably increased our understanding of their molecular characteristics and relaxed specificity. These insights enabled us to exploit these modification enzymes for developing new lantibiotic variants with improved therapeutic potential. Several methodologies have been explored to engineer novel lantibiotics. Here, we outline the current knowledge of modification enzymes. We also describe the methodologies and strategies used to engineer lantibiotics and provide some examples of successful generation of lantibiotics with enhanced activity.
UR - http://www.scopus.com/inward/record.url?scp=79960030559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960030559&partnerID=8YFLogxK
U2 - 10.2174/138920111796117355
DO - 10.2174/138920111796117355
M3 - Article
C2 - 21470152
AN - SCOPUS:79960030559
SN - 1389-2010
VL - 12
SP - 1221
EP - 1230
JO - Current Pharmaceutical Biotechnology
JF - Current Pharmaceutical Biotechnology
IS - 8
ER -